Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
Go back to Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria| ENANTA PHARM (NASDAQ: ENTA) | Delayed: 13.37 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.37 | 52 Week High | $34.49 | |||
| Open | $13.37 | 52 Week Low | $20.39 | |||
| Day High | $13.37 | P/E | N/A | |||
| Day Low | $13.37 | EPS | $-3.18 | |||
| Volume | 416 | |||||
